3-(N-ethyl-N-butylamino)propanol | 27453-44-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(N-ethyl-N-butylamino)propanol
• 英文别名: 3-[Butyl(ethyl)amino]propan-1-ol
• CAS: 27453-44-7
• 化学式: C₉H₂₁NO
• mdl: MFCD12179424
• 分子量: 159.272
• InChiKey: WVZTVLGQMVYJKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PROCESS FOR PREPARING (METH)ACRYLIC ACID
  申请人：Vogel Bernd

  公开号：US20100029979A1

  公开（公告）日：2010-02-04

  The present invention relates to a process for preparing (meth)acrylic acid, characterized in that a cyclic ester is converted to (meth)acrylic acid in the presence of a catalyst. The (meth)acrylic acid prepared can in particular be converted to (meth)acrylates.

  本发明涉及一种制备（甲基）丙烯酸的方法，其特征在于在催化剂的存在下将环状酯转化为（甲基）丙烯酸。制备的（甲基）丙烯酸可以特别地转化为（甲基）丙烯酸酯。
• PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE
  申请人：Vogel Bernd

  公开号：US20100010276A1

  公开（公告）日：2010-01-14

  The present invention relates to a process for preparing tetramethylglycolide by heating a composition which comprises at least 50% by weight of 2-hydroxy-isobutyric acid and/or tetramethylglycolide to a temperature of at least 100° C.

  本发明涉及一种制备四甲基乙二酰乙酯的方法，包括将含有至少50%重量的2-羟基异丁酸和/或四甲基乙二酰乙酯的组合物加热至至少100℃的温度。
• 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION
  申请人：OHTAKE Yasuhiro

  公开号：US20080076760A1

  公开（公告）日：2008-03-27

  The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

  本发明旨在提供一种以公式（1）表示的2,3,4,5-四氢-1H-1,5-苯并二氮平衍生物或其药学上可接受的盐，该化合物可作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药物。
• Heterocyclic Compounds
  申请人：Chen Dizhong

  公开号：US20090048300A1

  公开（公告）日：2009-02-19

  The present invention relates to compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to heterocyclic compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase (HDAC) activities.

  本发明涉及一种组合物，该组合物是组蛋白去乙酰化酶的抑制剂。更具体地，本发明涉及杂环化合物及其制备方法。这些化合物可能作为药物用于治疗增殖性疾病以及涉及、与或与组蛋白去乙酰化酶（HDAC）活性有关的其他疾病。
• COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT
  申请人：Goh Kay Lin

  公开号：US20100098691A1

  公开（公告）日：2010-04-22

  The present invention relates to a pharmaceutical composition for the treatment of cancer as well as methods of treatment of cancer that are based on the finding that certain benzimidazole based anti-cancer agents can be used in combination with a second anti-cancer agent to achieve desirable therapeutic outcomes. More specifically the present invention relates to a pharmaceutical composition including a benzimidazole based anti-cancer agent and a second anti-cancer agent. The invention also relates to methods of treatment of cancer including administration of a benzimidazole based anti-cancer agent and a second anti-cancer agent to a patient in need thereof.

  本发明涉及一种用于癌症治疗的制药组合物，以及基于发现某些基于苯并咪唑的抗癌药物可以与第二种抗癌药物结合使用以达到理想的治疗效果的癌症治疗方法。更具体地，本发明涉及一种包括基于苯并咪唑的抗癌药物和第二种抗癌药物的制药组合物。本发明还涉及癌症治疗方法，包括向需要治疗的患者施用基于苯并咪唑的抗癌药物和第二种抗癌药物。